1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Mar 2024
Admin
News Article

AstraZeneca Partners with Mankind to Distribute Asthma Drugs in India

AstraZeneca Pharma India, Mankind partner to accelerate access to asthma medicine in India

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths. It highlights a clear scope of improving the way asthma is managed in the country. AstraZenecaPharma India Limited and Mankind Pharma Limited entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.

IPR

AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.

India’s Contribution

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
It highlights a clear scope of improving the way asthma is managed in the country. ""The partnership with Mankind Pharma presents an opportunity to accelerate access and maximize the potential of our asthma drug as well as the turbuhaler which is a simple device, efficient in consistently delivering a higher proportion of respirable particles than the other devices. As much as we are excited to bring innovative medicine to India fast, we are equally invested on improving access strategically in the country,"" said Dr. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India.

Mankind on Agreement

Commenting on the agreement with AstraZeneca India, Atish Majumdar, Sr. President – Sales & Marketing, Mankind Pharma Limited said We are excited to partner with AstraZeneca to make their innovative therapy flagship brand Symbicort, a global standard in treating Asthma.
Symbicort's dual mechanism of action and ease of use in a single inhaler can greatly help patients manage these conditions and improve their quality of life.
Through our field forces’ extensive outreach, we hope to strengthen access across urban and rural markets. With our shared goal to enable better patient outcomes, I see this collaboration as strategic in more ways than one.
We believe such credible partnerships that widen availability of globally established medicines in India exemplify our ethos of putting patients first while ensuring value.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!